AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33208091 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measured using the Amsterdam Preoperative Anxiety and Information Scale and the Visual Analogue Scale for anxiety
Number of subjects: 190
Study 33208091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium measured using the Confusion Assessment Method for ICU and the 3 Minute Diagnostic Interview for Confusion Assessment Method
Number of subjects: 190
Study 33208091 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 190
Study 33208091 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living
Number of subjects: 190
Study 33208091 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 190
Study 33208091 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on cardiopulmonary bypass
Number of subjects: 190
Study 35350100 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 50
Study 35350100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34429952 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of tranexamic acid (TXA) 500mg/5 mL, total 10 mL at the surgical site.
Number of subjects: 40
Study 34429952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA applied).
Number of subjects: 40
Study 35900820 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health education intervention (animated health videos and access to InfoSpots)
Number of subjects: 600
Study 35900820 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of InfoSpots
Number of subjects: 600
Study 33381577 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DGT-UKA
Number of subjects: 22
Study 33381577 — intervention group
Group type: COMPARATOR
Intervention: T-UKA
Number of subjects: 22
Study 33541343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Ethical Assessment (REA)
Number of subjects: 0
Study 34710071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericoital tenofovir 1% gel
Number of subjects: 0
Study 34710071 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 33073954 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek
Number of subjects: 0
Study 33073954 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch
Number of subjects: 0
Study 33073954 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle Optium Neo
Number of subjects: 0
Study 33073954 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour Next One
Number of subjects: 0
Study 33073954 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour Next
Number of subjects: 0
Study 34480579 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 63
Study 34480579 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 100 mg
Number of subjects: 63
Study 34480579 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 150 mg
Number of subjects: 63
Study 34480579 — intervention group
Group type: COMPARATOR
Intervention: Suvorexant 150 mg
Number of subjects: 63
Study 34480579 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 30 mg
Number of subjects: 63
Study 34480579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34547081 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower infusion rate (333 mL/h)
Number of subjects: 11052
Study 34547081 — intervention group
Group type: COMPARATOR
Intervention: Control infusion rate (999 mL/h)
Number of subjects: 11052
Study 32989082 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As-based clinician-delivered smoking cessation counseling intervention
Number of subjects: 120
Study 32989082 — intervention group
Group type: COMPARATOR
Intervention: Social media counseling (attentional control)
Number of subjects: 120
Study 33750627 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-generated whole body vibration
Number of subjects: 24
Study 33750627 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated whole body vibration
Number of subjects: 24
Study 33750627 — intervention group
Group type: COMPARATOR
Intervention: Placebo vocal resting group (voice rest)
Number of subjects: 24
Study 34419868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-physical dual-task training based on fairy tales (60-90 min once a week for 12 weeks)
Number of subjects: 9
Study 32715513 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention, 8-week group-delivered
Number of subjects: 65
Study 34041527 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear activator treatment in mixed dentition (MD) starting at age 9
Number of subjects: 56
Study 34041527 — intervention group
Group type: COMPARATOR
Intervention: Headgear activator treatment in late mixed dentition (LMD) starting at age 11
Number of subjects: 56
Study 32811168 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN 63 Gel Stent
Number of subjects: 11
Study 32993799 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 23
Study 32993799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 33485062 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 3000 randomly selected SNPs
Number of subjects: 0
Study 33485062 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing experiment
Number of subjects: 0
Study 34419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone solution intake 31‐60 minutes before procedure (group 2)
Number of subjects: 302
Study 34419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone solution intake 20‐30 minutes before procedure (group 1)
Number of subjects: 302
Study 34419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone solution intake > 60 minutes before procedure (group 3)
Number of subjects: 302
Study 34419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction scores immediately after examination
Number of subjects: 302
Study 34419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction scores 2 hours after examination
Number of subjects: 302
Study 32216909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg
Number of subjects: 440
Study 32216909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg
Number of subjects: 440
Study 32216909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 36038370 — intervention group
Group type: EXPERIMENTAL
Intervention: Total extraperitoneal
Number of subjects: 243
Study 36038370 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 243
Study 32863148 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional flash glucose monitoring
Number of subjects: 288
Study 32863148 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study 32468987 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related ads
Number of subjects: 7991
Study 32468987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food ads
Number of subjects: 7991
Study 35594075 — intervention group
Group type: EXPERIMENTAL
Intervention: Full panretinal photocoagulation
Number of subjects: 207
Study 35594075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) with four monthly injections
Number of subjects: 207
Study 35594075 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified combination group with two bimonthly IVB injections and modified laser therapy
Number of subjects: 207
Study 34708929 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-shared, nurse-delivered cognitive-behavioral therapy for adherence and depression (CBT-AD)
Number of subjects: 161
Study 34708929 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 161
Study 35304120 — intervention group
Group type: EXPERIMENTAL
Intervention: AphasiaScripts (computer-based script training program) with high complexity
Number of subjects: 16
Study 35304120 — intervention group
Group type: COMPARATOR
Intervention: AphasiaScripts (computer-based script training program) with low complexity
Number of subjects: 16
Study 35304120 — intervention group
Group type: EXPERIMENTAL
Intervention: AphasiaScripts with high feedback
Number of subjects: 16
Study 35304120 — intervention group
Group type: COMPARATOR
Intervention: AphasiaScripts with low feedback
Number of subjects: 16
Study 32196976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 61-mg free acid capsules
Number of subjects: 30
Study 32196976 — intervention group
Group type: COMPARATOR
Intervention: Tafamidis meglumine 80-mg (4 × 20-mg) capsules
Number of subjects: 30
Study 32473644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Shockwave Therapy (SWT) during CABG surgery
Number of subjects: 80
Study 32473644 — intervention group
Group type: COMPARATOR
Intervention: CABG surgery with sham treatment
Number of subjects: 80
Study 35023346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-facilitated educational intervention for 3 months
Number of subjects: 402
Study 34143970 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus pegylated liposomal doxorubicin (PLD) (40 mg/m2 intravenously every 4 weeks)
Number of subjects: 566
Study 34143970 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 566
Study 34143970 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) alone
Number of subjects: 566
Study 32051303 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (four doses of 10 mg each)
Number of subjects: 722
Study 32051303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosing regime as melatonin)
Number of subjects: 722
Study 32051303 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 722
Study 35388276 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene/Sildenafil (C/S)
Number of subjects: 595
Study 35388276 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 595
Study 34981479 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin capsules with piperine supplement (500 mg/day, 95% curcuminoids) for 8 weeks
Number of subjects: 72
Study 34981479 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 72
Study 36181455 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal stimuli
Number of subjects: 271
Study 36181455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low arousal stimuli
Number of subjects: 271
Study 36181455 — intervention group
Group type: COMPARATOR
Intervention: Neutral word presented with high arousal word
Number of subjects: 271
Study 34583760 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament suture
Number of subjects: 2050
Study 34583760 — intervention group
Group type: COMPARATOR
Intervention: Braided suture
Number of subjects: 2050
Study 32383985 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine augmentation
Number of subjects: 0
Study 32383985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 0
Study 32383985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35704960 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement containing standardized menthol, limonene, and gingerol, administered for 30 days in addition to standard treatment.
Number of subjects: 56
Study 35704960 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered for 30 days in addition to standard treatment.
Number of subjects: 56
Study 34256715 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet delivered Cognitive Behavior Therapy with exposure (ICBT)
Number of subjects: 309
Study 34256715 — intervention group
Group type: COMPARATOR
Intervention: Internet delivered Cognitive Behavior Therapy without exposure (ICBT-WE)
Number of subjects: 309
Study 34256715 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 309
Study 32217746 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33257279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 25 mg kg−1 every 24 hours
Number of subjects: 30
Study 33257279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 12.5 mg kg−1 every 12 hours
Number of subjects: 30
Study 33257279 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 0.1 mg kg−1 every 24 hours
Number of subjects: 30
Study 33257279 — intervention group
Group type: COMPARATOR
Intervention: Rescue analgesia (tramadol, 2 mg kg−1 IV)
Number of subjects: 30
Study 33239135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside treatment
Number of subjects: 80
Study 33239135 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 80
Study 36775530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (n = 16)
Number of subjects: 34
Study 36775530 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 34
Study 33991178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose co-transporter-2 inhibitors (SGLT2i)
Number of subjects: 515
Study 34147692 — intervention group
Group type: COMPARATOR
Intervention: 0 units of pituitrin
Number of subjects: 118
Study 34147692 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 units of pituitrin
Number of subjects: 118
Study 34147692 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 units of pituitrin
Number of subjects: 118
Study 34147692 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 units of pituitrin
Number of subjects: 118
Study 33044441 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 10
Study 33044441 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 10
Study 32531428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ng/kg lipopolysaccharide (LPS) as inflammatory stimulus
Number of subjects: 40
Study 32531428 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline as placebo
Number of subjects: 40
Study 35377518 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin injections (12 units, 1:2.5)
Number of subjects: 15
Study 35377518 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin injections (6 units, 1:5)
Number of subjects: 15
Study 35377518 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin injections (4 units, 1:7.5)
Number of subjects: 15
Study 35377518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline injection
Number of subjects: 15
Study 35377518 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 34215615 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 800
Study 34215615 — intervention group
Group type: COMPARATOR
Intervention: Control (non-HC treatment)
Number of subjects: 800
Study 32956891 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel shiny model for predicting survival
Number of subjects: 265
Study 32956891 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sample analysis
Number of subjects: 265
Study 32956891 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation sample analysis
Number of subjects: 265
Study 36003008 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 36003008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33980691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity-increasing alleles (UFA)
Number of subjects: 0
Study 33980691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity-decreasing alleles (FA)
Number of subjects: 0
Study 33980691 — intervention group
Group type: COMPARATOR
Intervention: UFA
Number of subjects: 0
Study 33980691 — intervention group
Group type: COMPARATOR
Intervention: FA
Number of subjects: 0
Study 33202219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily for 30 days)
Number of subjects: 1910
Study 33202219 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300–600 mg loading dose, 75 mg daily for 30 days)
Number of subjects: 1910
Study 33202219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1910
Study 33202219 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1910
Study 36189651 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynucleotides and hyaluronic acid based gel
Number of subjects: 50
Study 33356408 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Nutrition Facts label (single column)
Number of subjects: 992
Study 33356408 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Nutrition Facts label (dual column)
Number of subjects: 992
Study 33356408 — intervention group
Group type: COMPARATOR
Intervention: Original Nutrition Facts label
Number of subjects: 992
Study 32565458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen + oral hydromorphone
Number of subjects: 536
Study 32565458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen + oral acetaminophen
Number of subjects: 536
Study 32565458 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen alone
Number of subjects: 536
Study 35328964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial training (twice per week for 6 weeks, training load of about 70% of maximal force)
Number of subjects: 24
Study 35328964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial training
Number of subjects: 24
Study 35328964 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 35328964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial training and Control group
Number of subjects: 24
Study 33974370 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic ophthalmic solution of 0.5% ozonised oil in liposomes plus hypromellose treatment (2 drops 4 times/day)
Number of subjects: 174
Study 33974370 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 174
Study 32525413 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month home-based exercise program
Number of subjects: 98
Study 32525413 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (one guidance session for light home-exercises)
Number of subjects: 98
Study 32205125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 89
Study 32205125 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 89
Study 32419540 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 21
Study 32419540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2-assisted photodynamic therapy (FrCO2 + PDT)
Number of subjects: 21
Study 32507160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training at moderate intensity (11-15/20 on the Borg scale), 3 times a week for 8 weeks.
Number of subjects: 28
Study 32507160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training).
Number of subjects: 28
Study 616279764 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based competition (Regions Conference Cup)
Number of subjects: 13
Study 35862038 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine ω-3 fatty acid supplementation
Number of subjects: 0
Study 35862038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34719908 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation in motion during therapeutic gymnastics
Number of subjects: 51
Study 34719908 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic gymnastics recommended for lymphovenous insufficiency (Control)
Number of subjects: 51
Study 32925788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding treatment
Number of subjects: 70
Study 32925788 — intervention group
Group type: COMPARATOR
Intervention: Climen tablet (0.3 mg, 1 tablet/day)
Number of subjects: 70
Study 36070301 — intervention group
Group type: EXPERIMENTAL
Intervention: oral alfacalcidol
Number of subjects: 976
Study 34684348 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Habits Plus (six telephone calls)
Number of subjects: 458
Study 34684348 — intervention group
Group type: EXPERIMENTAL
Intervention: Time2bHealthy (six online modules)
Number of subjects: 458
Study 34684348 — intervention group
Group type: COMPARATOR
Intervention: Active control (ten information sheets and a summary booklet)
Number of subjects: 458
Study 35201381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation of the left posterior parietal cortex (2 mA for 20 min) followed by motor practice
Number of subjects: 28
Study 35201381 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation followed by motor practice
Number of subjects: 28
Study 34076288 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy (Group PVI/SP)
Number of subjects: 203
Study 34076288 — intervention group
Group type: COMPARATOR
Intervention: Control (Group PVI alone)
Number of subjects: 203
Study 32176744 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal cancer patients with ERF
Number of subjects: 46
Study 32176744 — intervention group
Group type: COMPARATOR
Intervention: Esophageal cancer patients without ERF (Control)
Number of subjects: 46
Study 32176744 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal fold paralysis in ERF
Number of subjects: 46
Study 36327532 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based emotional awareness and expression therapy (I‐EAET) for 10 weeks
Number of subjects: 74
Study 36327532 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 74
Study 34530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice a day) plus Aspirin (100 mg once a day)
Number of subjects: 1086
Study 34530594 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (5 mg twice a day) alone
Number of subjects: 1086
Study 34530594 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once a day) alone
Number of subjects: 1086
Study 35225542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with multilayered inverted internal limiting membrane flap technique (Group B)
Number of subjects: 150